Research shown at the EADV Congress 2026 found 39% of users reported nails lifting versus 9% of non-users, plus more hair loss. It's self-reported and shows no causation.
Recap by typeshit. Full story at VICE.
European regulators first raised NAION, a rare optic nerve condition sometimes called an eye stroke, as a possible risk more than 15 months ago.
Obesity doctor Spencer Nadolsky takes on six popular misconceptions about Ozempic in a quick social video. The caption doesn't say which myths are covered.
Users described more appetite, fatigue, extra energy and insomnia. An analysis of Reddit comments, not a clinical trial, so the findings come from self-reports.
Online sellers pitch peptides for weight loss, anti-aging and muscle gain, and Gavin Coote's full story looks at the risks of products nobody regulates.
The biotech has stopped a weight loss maintenance trial of its weekly GLP-1 pill. FirstWord Pharma has the details on the decision.
Medscape reports national prescription data showing the pill reached that mark within two months of its January 2026 launch, with faster early uptake than injectable tirzepatide or semaglutide.
Loading…